Search

Search Results

• 

  Evaluation of Th9 lymphocytes in peripheral blood of rheumatoid arthritis patients and correlation with anti-tumor necrosis factor therapy: results from an in vitro pivotal study

  R. Talotta, A. Berzi, F. Atzeni, D. Dell'Acqua, P. Sarzi Puttini, D. Trabattoni

  83-89

  09-09-2016

  https://doi.org/10.4081/reumatismo.2016.875

  2058

  PDF: 998

  IL RUOLO DEI LINFOCITI TH9 NELL'ARTRITE REUMATOIDE E NELLA RISPOSTA AL TRATTAMENTO CON INFLIXIMAB.: 607

• PO:12:183 | Acute effect of anti-TNF therapy on atrioventricular conduction in chronic inflammatory arthritis: a prospective cohort study Viola Salvini¹, Riccardo Accioli¹, Anna Cantore¹, Fabio Salvadori¹, Enrico Selvi², Virgina Berlengerio², Maurizio Acampa³, Alessandra Cartocci¹, Decoroso Verrengia¹, Kateryna Miedviedieva¹, Sciaila Bernardini¹, Michele Voglino¹, Maurizio Bicchi¹, Daniela Merlotti¹, Stefania Bisogno¹, Pier Leopoldo Capecchi¹, Pietro Enea Lazzerini¹ | ¹Division of Internal Medicine, Electroimmunology Unit, University Hospital of Siena, Italy; ²Division of Rheumatology, University Hospital of Siena, Italy; ³Stroke Unit, University Hospital of Siena, Italy

  Società Italiana di Reumatologia

  18-03-2026

  https://doi.org/10.4081/reumatismo.2025.2315

  39

• Incidence and management of infusion reactions to infliximab in 186 italian patient’s with rheumatoid arthritis: the Padua experience

  C. Botsios, P. Ostuni, S. Todesco

  44-51

  https://doi.org/10.4081/reumatismo.2005.44

  1275

  PDF: 1818

• Long-term evaluation of infliximab in the treatment of persistently active juvenile idiopathic arthritis refractory to conventional therapy

  G. De Marco, V. Gerloni, I. Pontikaki, A. Lurati, B. Teruzzi, A. Salmaso, E. Valcamonica, M. Gattinara, F. Fantini

  50-56

  https://doi.org/10.4081/reumatismo.2007.50

  1274

  PDF: 876

• Antinuclear, anti-dsDNA and anti-ENA antibodies in patients affected with rheumatoid arthritis or ankylosing spondylitis during treatement with infliximab

  A. Hoxha, A. Ruffatti, P. Grypiotis, M. Podswiadek, C. Botsios, U. Fiocco, L. Punzi, S. Todesco

  121-126

  https://doi.org/10.4081/reumatismo.2006.121

  2056

  PDF: 1781
• 

  A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy

  A. Notarnicola, F. Iannone, G. Lopalco, M. Covelli, G. Lapadula

  298-301

  17-03-2014

  https://doi.org/10.4081/reumatismo.2013.727

  2587

  PDF: 1170
• 

  Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs

  F.M. Perrotta, O. Addimanda, R. Ramonda, S. D’Angelo, E. Lubrano, A. Marchesoni, I. Olivieri, L. Punzi, C. Salvarani, A. Spadaro

  208-214

  06-11-2014

  https://doi.org/10.4081/reumatismo.2014.756

  2916

  PDF: 1605
• 

  Intra-articular therapy with tumor necrosis factor-α antagonists: an update

  S. Bello, C. Bonali, L. Serafino, C. Rotondo, N. Terlizzi, G. Lapadula

  257-263

  14-03-2014

  https://doi.org/10.4081/reumatismo.2013.721

  2808

  PDF: 1350

• PO:36:243 | Drug survival, discontinuation reasons and disease activity in patients with Behçet's disease treated with infliximab - a real-life study Antonello Sulis¹, Federica Di Cianni¹, Maria Laura Manca², Rosaria Talarico¹, Marta Mosca¹. | ¹Rheumatology Unit of Pisa, University of Pisa, Pisa, Italy, Pisa, Italy; ²Department of Clinical and Experimental Medicine and Department of Mathematics, University of Pisa, Italy, Pisa, Italy.

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2091

  147
• 

  Infliximab as successful treatment option in a case of adenosine deaminase 2 deficiency

  M.B. Ates, S. Karup, S. Ugurlu

  19-12-2023

  https://doi.org/10.4081/reumatismo.2023.1543

  1554

  PDF: 489
• 

  Infliximab in the treatment of Budd-Chiari syndrome in Behçet’s disease

  L.B. Santos, J. Rigueira, A.P. Vilas

  163-165

  24-10-2019

  https://doi.org/10.4081/reumatismo.2019.1153

  1569

  PDF: 909

• The treatment of recurrent uveitis with TNFα inhibitors

  P.C.F. Falappone, F. Iannone, C. Scioscia, V. Grattagliano, M. Covelli, G. Lapadula

  185-189

  https://doi.org/10.4081/reumatismo.2004.185

  1909

  PDF: 2515

• Infliximab therapy for Crohn’s disease in the presence of chronic hepatitis C infection - Reply

  M. Galeazzi

  112

  https://doi.org/10.4081/reumatismo.2003.112

  846

  PDF: 661
• 

  Psoriatic arthritis: treatment strategies using biologic agents

  S. D'Angelo, C. Palazzi, I. Olivieri

  113-121

  05-06-2012

  https://doi.org/10.4081/reumatismo.2012.113

  1438

  PDF: 1219

• Sustained response to infliximab treatment in two cases of early rheumatoid arthritis that has been maintained after drug withdrawal

  P. Caramaschi, S. Pieropan, A. Volpe, A. Carletto, L.M Bambara, D. Biasi

  221-223

  https://doi.org/10.4081/reumatismo.2008.221

  884

  PDF: 1416

• Polyarthritis flare in patient with ankylosing spondylitis treated with infliximab

  M. Gutierrez, A. Becciolini, C. Bertolazzi, L. Di Geso, M. Tardella, A. Ariani, E. Filippucci, W. Grassi

  221-224

  https://doi.org/10.4081/reumatismo.2010.221

  1300

  PDF: 785

• Case report: AREB in a patient with rheumatoid arthritis treated with methotrexate and infliximab

  Giuseppe D'Alessandro, Maria Rosaria Bianco, Spiridon Politis, Celestino Ferrandina, Giuseppe Rossi, Emanuele Altomare

  59-61

  https://doi.org/10.4081/reumatismo.2006.59

  1034

  PDF: 967

• Diffused suberitrodermic psoriasis induced by infliximab

  V. Bruzzese

  328-331

  https://doi.org/10.4081/reumatismo.2007.328

  976

  PDF: 1158

• Intra-articular therapy with infliximab in psoriatic arthritis: efficacy and safety in refractory monoarthritis

  S. Bello, C. Bonali, L. Serafino, P. Di Giuseppe, A. Minosi, N. Terlizzi

  46-50

  https://doi.org/10.4081/reumatismo.2010.46

  1206

  PDF: 1394

• Side effects of anti-TNFa therapy in juvenile idiopathic arthritis

  Irene Pontikaki, Valeria Gerloni, Maurizio Gattinara, Alfredomaria Lurati, Alessandra Salmaso, Gabriele De Marco, Barbara Teruzzi, Elisabetta Valcamonica, Flavio Fantini

  31-38

  https://doi.org/10.4081/reumatismo.2006.31

  1903

  PDF: 2615

• PO:02:024 | Development of anti-drug antibodies in patients with peripheral and/or axial spondyloarthritis treated with infliximab or adalimumab: a monocentric cross-sectional study Gabriele Amati¹, Gilda Sandri^1|2, Alessandra Melegari³, Benedetta Bongiovanni^1|2, Giovanni Ciancio², Martina Orlandi^1|2, Ottavio Secchi¹, Dilia Giuggioli^1|2 | ¹Struttura complessa di Reumatologia, Azienda Ospedaliero-Universitaria Policlinico di Modena; ²Cattedra di Reumatologia, Università degli studi di Modena e Reggio Emilia; ³Dipartimento di medicina di laboratorio, Ospedale di Baggiovara, AUSL di Modena, Italy

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2126

  149

• Safety of anti-TNFa biological drugs

  F. Trotta, G. Valentini

  34-39

  https://doi.org/10.4081/reumatismo.2005.4s.34

  1300

  PDF: 1403

• PO:22:032 | Beyond the joints: a rare case of subcorneal pustular dermatosis in Rheumatoid Arthritis Sara Casella^1|2, Carlo Smirne^1|2, Roberta Zaira Pedrazzoli³, Mattia Perazzi^1|3, Edoardo Cammarata⁴, Francesca Zottarelli⁴, Paola Savoia⁵, Renzo Boldorini⁶, Mario Pirisi^1|2, Pier Paolo Sainaghi^1|3 | ¹Dipartimento di Medicina Traslazionale, Università del Piemonte Orientale Novara, Italy; ²Unità di Medicina Interna, Azienda Ospedaliera Maggiore della Carità Novara, Italy; ³Unità di Medicina Interna e Reumatologia, Azienda Ospedaliera Maggiore della Carità Novara, Italy; ⁴Unità di Dermatologia, Azienda Ospedaliera Maggiore della Carità Novara, Italy; ⁵Dipartimento di Scienze della salute, Università del Piemonte Orientale Novara, Italy; ⁶Unità di Anatomia Patologica, Azienda Ospedaliera Maggiore della Carità Novara, Italy

  Società Italiana di Reumatologia

  18-03-2026

  https://doi.org/10.4081/reumatismo.2025.2345

  32
• 

  A short history of anti-rheumatic therapy - VII. Biological agents

  G. Pasero, P. Marson, B. Gatto

  185-194

  09-11-2011

  https://doi.org/10.4081/reumatismo.2011.185

  1696

  PDF: 1316

• Biologic therapy with anti-TNFa in spondyloarthritides and other autoimmune diseases

  G. Lapadula

  22-29

  https://doi.org/10.4081/reumatismo.2005.4s.22

  926

  PDF: 1163
• 

  GISEA: an Italian biological agents registry in rheumatology

  G. Lapadula, G. Ferraccioli, C. Ferri, L. Punzi, F. Trotta

  155-164

  09-11-2011

  https://doi.org/10.4081/reumatismo.2011.155

  2627

  PDF: 1677

• Biologic therapy with anti-TNFa in rheumathoid atrhritis

  G. Ferraccioli

  17-21

  https://doi.org/10.4081/reumatismo.2005.4s.17

  860

  PDF: 736

• Analysis of the kinetic of expression of tristetraprolin and HuR by rheumatoid arthritis patients pheripheral blood mononuclear cells stimulated with lipopolysaccharide

  M. Fabris, B. Tolusso, E. Gremese, P. Tomietto, G. Ferraccioli

  94-103

  https://doi.org/10.4081/reumatismo.2004.94

  1526

  PDF: 990
• 

  Development of thymoma without myasthenia gravis in a patient with radiographic axial spondyloarthritis treated with tumor necrosis factor-α inhibitors

  Piera Altieri, Francesco Maria Mariani, Evy Di Ruscio, Francesco Carubbi, Claudio Ferri, Alessia Alunno

  05-06-2025

  https://doi.org/10.4081/reumatismo.2025.1693

  2445

  PDF: 132

• Differences in pharmacology of tumor necrosis factor (TNF) antagonists

  U. Fiocco, S. Bombardieri

  8-16

  https://doi.org/10.4081/reumatismo.2005.4s.8

  1340

  PDF: 1822

• Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: biological mechanisms and clinical aspects

  C. Botsios, P. Ostuni, P. Sfriso, A. Furlan, U. Fiocco, D. Sgarabotto, S. Todesco

  224-235

  https://doi.org/10.4081/reumatismo.2003.224

  1272

  PDF: 2719

• Recurrent new-onset uveitis in a patient with rheumatoid arthritis during anti-TNFα treatment

  M. Di Gangi, R. Foti, R. Leonardi, C. Leonetti, P. Castellino

  169-172

  https://doi.org/10.4081/reumatismo.2007.169

  1162

  PDF: 1070
• 

  Inflammatory back pain as an unusual manifestation of Takayasu arteritis: a case report

  Faiq Gorial, Nabaa Awadh, Ali Al-Shakarchi, Ghaith Al-Gburi

  30-10-2024

  https://doi.org/10.4081/reumatismo.2024.1678

  2140

  PDF: 430

• Effects of TNF antagonists on immune and neuroendocrine system

  G. Valesini, M. Cutolo

  3-7

  https://doi.org/10.4081/reumatismo.2005.4s.3

  1410

  PDF: 847

• TNF-alpha and insulin-resistance: metabolic effects of in vivo therapeutic blockade

  F. Ursini

  254-259

  https://doi.org/10.4081/reumatismo.2009.254

  1734

  PDF: 2404

• A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens

  Giovanna Cuomo, Gabriella Molinaro, Giovanni La Montagna, Sergio Migliaresi, Gabriele Valentini

  22-25

  https://doi.org/10.4081/reumatismo.2006.22

  1657

  PDF: 2079
• 

  Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis

  G. Andrisani, E. Gremese, L. Guidi, A. Papa, M. Marzo, C. Felice, D. Pugliese, A. Armuzzi

  75-78

  27-05-2013

  https://doi.org/10.4081/reumatismo.2013.75

  3132

  PDF: 1002

• Anti-TNFa treatment in patients with rheumatoid arthritis and anti-Ro/SSA antibodies

  I. Cavazzana, F. Franceschini, E. Danieli, M. Frassi, M. Vianelli, R. Gorla, P. Airò, R. Cattaneo

  267-272

  https://doi.org/10.4081/reumatismo.2005.267

  1222

  PDF: 1841

• Infliximab treatment in a case of rheumatoid scleromalacia perforans

  R. Herrera-Esparza, E. Avalos-Diaz

  212-215

  https://doi.org/10.4081/reumatismo.2009.212

  1335

  PDF: 1072

• Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis

  C. Botsios, P. Sfriso, A. Furlan, P. Ostuni, M. Biscaro, U. Fiocco, S. Todesco, L. Punzi

  32-37

  https://doi.org/10.4081/reumatismo.2007.32

  1884

  PDF: 838

• Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature

  R. Scrivo, F. Conti, F.R. Spinelli, S. Truglia, L. Magrini, M. Di Franco, F. Ceccarelli, G. Valesini

  107-117

  https://doi.org/10.4081/reumatismo.2009.107

  2057

  PDF: 1238

• Approved indications and other possible utilizations of anti-TNFa biologic drugs

  W. Grassi, C. Montecucco

  30-33

  https://doi.org/10.4081/reumatismo.2005.4s.30

  1329

  PDF: 926

• Are there any positive effects of TNF-alpha blockers on bone metabolism?

  B. Seriolo, S. Paolino, A. Sulli, M. Cutolo

  199-205

  https://doi.org/10.4081/reumatismo.2006.199

  1432

  PDF: 1251

• Correlation between radiographic, echographic and MRI changes and rheumatoid arthritis progression

  M.A. Cimmino, M. Parodi, E. Silvestri, G. Garlaschi

  28-40

  https://doi.org/10.4081/reumatismo.2004.1s.28

  1133

  PDF: 3007

• Blocking TNF in vitro with infliximab determines the inhibition of expansion and interferon gamma production of Vγ9/Vδ2 T lymphocytes from patients with active rheumatoid arthritis. A role in the susceptibility to tuberculosis?

  A.R. Giardina, A. Accardo-Palumbo, F. Ciccia, A. Ferrante, A. Principato, R. Impastato, G. Triolo

  21-26

  https://doi.org/10.4081/reumatismo.2009.21

  1557

  PDF: 1202

• PO:37:266 | Long-term manifestation of graft-versus-host disease presenting as a vasculitic-like syndrome: a rare case report Camilla Mazzanti¹, Gianluca Santoboni¹, Claudio Angrisani¹, Massimiliano De Simone¹, Giuliana Marciani¹, Alessandra Fiorentini¹ | ¹Ospedale Santa Rosa Viterbo, Italy

  Società Italiana di Reumatologia

  18-03-2026

  https://doi.org/10.4081/reumatismo.2025.2391

  17